RT Journal Article
SR Electronic
T1 Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.12.21267518
DO 10.1101/2021.12.12.21267518
A1 Titov, Aleksei
A1 Shaykhutdinova, Regina
A1 Shcherbakova, Olga V.
A1 Serdyuk, Yana
A1 Sheetikov, Savely A.
A1 Zornikova, Ksenia V.
A1 Maleeva, Alexandra V.
A1 Khmelevskaya, Alexandra
A1 Dianov, Dmitry V.
A1 Shakirova, Naina T.
A1 Malko, Dmitry B.
A1 Shkurnikov, Maxim
A1 Nersisyan, Stepan
A1 Tonevitsky, Alexander
A1 Khamaganova, Ekaterina
A1 Ershov, Anton V.
A1 Osipova, Elena Y.
A1 Nikolaev, Ruslan V.
A1 Pershin, Dmitry E.
A1 Vedmedskia, Viktoria A.
A1 Maschan, Mikhail
A1 Ginanova, Victoria
A1 Efimov, Grigory A.
YR 2021
UL http://medrxiv.org/content/early/2021/12/13/2021.12.12.21267518.abstract
AB The ongoing COVID-19 pandemic calls for more effective diagnostic tools, and T cell response assessment can serve as an independent indicator of prior COVID-19 exposure while also contributing to a more comprehensive characterization of SARS-CoV-2 immunity. In this study, we systematically assessed the immunogenicity of 118 epitopes with immune cells collected from multiple cohorts of vaccinated, convalescent, and healthy unexposed and SARS-CoV-2 exposed donors. We identified seventy-five immunogenic epitopes, 24 of which were immunodominant. We further confirmed HLA restriction for 49 epitopes, and described association with more than one HLA allele for 14 of these. After excluding two cross-reactive epitopes that generated a response in pre-pandemic samples, we were left with a 73-epitope set that offers excellent diagnostic specificity without losing sensitivity compared to full-length antigens, which evoked a robust cross-reactive response. We subsequently incorporated this set of epitopes into an in vitro diagnostic ‘Corona-T-test’ which achieved a diagnostic accuracy of 95% in a clinical trial. When applied to a cohort of asymptomatic seronegative individuals with a history of prolonged SARS-CoV-2 exposure, this test revealed a lack of specific T cell response combined with strong cross-reactivity to full-length antigens, indicating that abortive infection had occurred in these individuals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by a Russian Science Foundation grant 20-15-00395 (G.A.E.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the National research center for Hematology gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors